^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    OMTX705

    i
    Other names: OMTX705
    Associations

    News

    Trials
    Company:
    InxMed, Oncomatryx
    Drug class:
    Microtubule inhibitor, FAPα-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    4years
    OMTX705, a Novel FAP-Targeting ADC demonstrates Activity in Chemotherapy and PD1-Resistant Solid Tumors Models. (PubMed, Clin Cancer Res)
    These data suggest that FAP-targeting with OMTX705 represents a novel and potent strategy for cancer treatment including tumors resistant to immunotherapy and support its clinical development.
    Journal
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • PRF1 (Perforin 1)
    |
    OMTX705